284462-92-6

Basic information

• Product Name: 2-Pyridinecarboxamide, 4-(5-amino-2-methylphenoxy)-N-methyl-
• Synonyms: 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline
• CAS NO: 284462-92-6
• Molecular Formula: C14H15N3O2
• Molecular Weight: 257.292
• Mol File: 284462-92-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-Pyridinecarboxamide, 4-(5-amino-2-methylphenoxy)-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxamide, 4-(5-amino-2-methylphenoxy)-N-methyl-(284462-92-6)
• EPA Substance Registry System: 2-Pyridinecarboxamide, 4-(5-amino-2-methylphenoxy)-N-methyl-(284462-92-6)

Safety Data

• Hazardous Substances Data: 284462-92-6(Hazardous Substances Data)

Upstream product

• 2835-95-2 amino-4 hydroxy-2 toluene 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 284462-78-8 4-(3-aminophenoxy)-N-methylpicolinamide 
• 41513-02-4 4-bromo-3-(trifluoromethyl)phenyl isocyanate 
• 393-36-2 4-bromo-3-(trifluoromethyl)aniline 
• 284462-44-8 4-(4-amino-3-chloro-phenoxy)-pyridine-2-carboxylic acid methylamide 
• 16588-75-3 2-methoxy-5-trifluoromethylphenyl isocyanate 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 
• 864272-32-2 C₁₄H₁₃N₃O₄ 

Downstream Products

• 864272-33-3 C₁₄H₁₆N₄O₂ 

Relevant articles and documents

SEMICARBAZIDE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.